Phenytoin Administration Guidelines

Introduction to Phenytoin Administration

• Therapeutic serum phenytoin levels (10-20 mcg/mL) are typically achieved within minutes after completion of the infusion, as recommended by the American College of Emergency Physicians 1, 2

Monitoring and Administration

• Monitor vital signs closely, especially blood pressure and heart rate via ECG, as suggested by the American Heart Association 3
• Reduce infusion rate or discontinue if heart rate decreases by 10 beats per minute, according to the American College of Cardiology 3
• Monitor for neurological side effects including ataxia, nystagmus, tremor, and somnolence, as advised by the American Academy of Neurology 2

Alternative Administration Methods

• Fosphenytoin (a water-soluble prodrug of phenytoin) can be administered at 18 PE/kg IV at a maximum rate of 150 PE/min, as recommended by the American College of Emergency Physicians 3, 4
• Fosphenytoin has fewer adverse events compared to IV phenytoin loading, according to the American College of Clinical Pharmacology 3, 2

Oral Administration Guidelines

• Oral loading of phenytoin can be administered as 20 mg/kg divided in maximum doses of 400 mg every 2 hours, as suggested by the American Academy of Clinical Toxicology 4
• Therapeutic serum phenytoin levels are typically achieved between 3-8 hours after initial ingestion, according to the American College of Clinical Pharmacology 2

Potential Complications

• IV phenytoin contains propylene glycol (40%) and ethanol (10%) with pH of 12, contributing to adverse effects, as noted by the American College of Medical Toxicology 2
• Purple glove syndrome, tissue necrosis, and phlebitis are potential complications of IV phenytoin, as warned by the American College of Emergency Physicians 2

Guidelines for Safe Intravenous Phenytoin Administration

Cardiac Arrhythmias Associated with IV Phenytoin

• Intravenous phenytoin can cause bradycardia and various degrees of heart block, including junctional bradycardia, in both adult and pediatric patients 5.

Infusion Rate Recommendations

• In pediatric patients, the infusion rate must not exceed 1–3 mg/kg/min or 50 mg/min, whichever is slower 5.
• The infusion rate should be reduced promptly if the patient’s heart rate falls by ≥10 beats per minute 5.

Formulation and Dilution Requirements

• IV phenytoin must be diluted exclusively in normal saline; it is incompatible with glucose‑containing solutions 5.

Preference for Fosphenytoin

• Fosphenytoin is associated with fewer adverse cardiovascular events compared with IV phenytoin 5.
• The American Academy of Pediatrics recommends using fosphenytoin when available because it carries a lower risk of cardiac toxicity 5.

Management of Extravasation Injuries

• Extravasation of IV phenytoin can lead to severe skin injury, including necrosis and tissue damage 5.

Cardiovascular Risks of Intravenous Phenytoin and Advantages of Fosphenytoin

Formulation‑Related Cardiac Toxicity

• The intravenous phenytoin formulation contains ≈ 40 % propylene glycol and ≈ 10 % ethanol at pH 12, which are major contributors to its cardiac toxicity. 6

Safety Recommendations for Intravenous Phenytoin

• During IV phenytoin infusion, the infusion rate should be reduced immediately if the patient’s heart rate falls by ≥ 10 beats per minute. 7
• IV phenytoin must be diluted only in normal saline and never in dextrose solutions. 7

Benefits of Fosphenytoin Over IV Phenytoin

• Fosphenytoin is strongly preferred because it is associated with significantly fewer cardiovascular adverse events compared with IV phenytoin. 6
• The water‑soluble fosphenytoin formulation lacks propylene glycol and ethanol, eliminating the formulation‑related cardiac toxicity seen with phenytoin. 6
• Clinical data show a lower incidence of hypotension, bradycardia, and arrhythmias when fosphenytoin is used instead of IV phenytoin. 6

Oral Phenytoin Loading in Stable Patients

• An oral loading regimen of 20 mg/kg divided into 400 mg doses every 2 hours attains therapeutic serum levels within 3–8 hours while posing minimal cardiac risk. 6